Literature DB >> 11892059

Vaccine prevention of acute otitis media.

D P Greenberg1, A Hoberman.   

Abstract

The incidence of acute otitis media (AOM) in infants and young children has increased dramatically in recent years in the United States. AOM often follows upper respiratory tract infections due to pathogens such as respiratory syncytial virus (RSV), influenza virus, and parainfluenza virus (PIV). These viruses cause eustachian tube dysfunction that is critical to the pathogenesis of AOM. Vaccines against these viruses would likely reduce the incidence of AOM. In three previous studies, influenza virus vaccines reduced the incidence of AOM by 30% to 36%. Vaccines to prevent infections with RSV and PIV type 3 are undergoing clinical testing at this time. Streptococcus pneumoniae, nontypeable Haemophilus influenzae (NTHi), and Moraxella catarrhalis are the three most common AOM pathogens. Heptavalent pneumococcal conjugate vaccine is effective in preventing invasive disease and AOM caused by serotypes contained in the vaccine. Vaccine candidates for NTHi and M. catarrhalis are under development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11892059      PMCID: PMC7089114          DOI: 10.1007/s11882-001-0049-8

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  44 in total

1.  Recommended childhood immunization schedule-United States, January-December 2001. Committee on Infectious Diseases.

Authors: 
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

Review 2.  Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review.

Authors:  D J Lim; Y M Chun; H Y Lee; S K Moon; K H Chang; J D Li; A Andalibi
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

Review 3.  The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.

Authors:  D E Briles; S K Hollingshead; G S Nabors; J C Paton; A Brooks-Walter
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

4.  Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study.

Authors:  D W Teele; J O Klein; B Rosner
Journal:  J Infect Dis       Date:  1989-07       Impact factor: 5.226

5.  Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.

Authors:  R A Karron; P F Wright; J E Crowe; M L Clements-Mann; J Thompson; M Makhene; R Casey; B R Murphy
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

6.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

Authors:  G S Nabors; P A Braun; D J Herrmann; M L Heise; D J Pyle; S Gravenstein; M Schilling; L M Ferguson; S K Hollingshead; D E Briles; R S Becker
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

7.  Influenza vaccination in the prevention of acute otitis media in children.

Authors:  T Heikkinen; O Ruuskanen; M Waris; T Ziegler; M Arola; P Halonen
Journal:  Am J Dis Child       Date:  1991-04

8.  Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

Authors:  R A Karron; M Makhene; K Gay; M H Wilson; M L Clements; B R Murphy
Journal:  Pediatr Infect Dis J       Date:  1996-08       Impact factor: 2.129

Review 9.  Vaccines for Moraxella catarrhalis.

Authors:  J C McMichael
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

10.  Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

Authors:  P A Piedra; S Grace; A Jewell; S Spinelli; D Bunting; D A Hogerman; F Malinoski; P W Hiatt
Journal:  Pediatr Infect Dis J       Date:  1996-01       Impact factor: 2.129

View more
  1 in total

1.  Acute otitis media in children-current treatment and prevention.

Authors:  Marie Gisselsson-Solen
Journal:  Curr Infect Dis Rep       Date:  2015-05       Impact factor: 3.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.